Mechanism of interaction of sitamaquine with Leishmania donovani

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 12, 2010, Pages 2548-2555

  Coimbra, E S ^a,b   Libong, D ^a   Cojean, S ^a,b   Saint Pierre Chazalet, M ^a,b,c   Solgadi, A ^d   Le Moyec, L ^b,e   Duenas Romero, A M ^a,b   Chaminade, P ^a   Loiseau, P M ^a,b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b CNRS   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d IPSIT   (France)

^e UNIVERSITÉ PARIS 13   (France)

Author keywords

Antileishmanial chemotherapy; Antiparasitic drugs; Mechanism of action

Indexed keywords

GLUCOSE; PHOSPHOLIPID; SITAMAQUINE; STEROL;

ANTIBIOTIC SENSITIVITY; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOSOL; DRUG MECHANISM; ISOTHERM; LEISHMANIA DONOVANI; LIPID COMPOSITION; NITROBLUE TETRAZOLIUM TEST; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE;

AMINOQUINOLINES; ANIMALS; ANTIPROTOZOAL AGENTS; BIOMIMETIC MATERIALS; CELL MEMBRANE; DIFFUSION; LEISHMANIA DONOVANI; MEMBRANE LIPIDS; PHOSPHOLIPIDS; STEROLS;

EID: 78149476218     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq371     Document Type: Article

References (22)

1. Croft SL. Kinetoplastida: new therapeutic strategies. Parasite 2008; 15: 522-7.
2. Dietze R, Carvalho S, Valli L et al. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am J Trop Med Hyg 2001; 65: 685-9.
3. Sherwood JA, Gachihi GS, Muigai RK et al. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clin Infect Dis 1994; 19: 1034-9.
4. Theoharides H, Chung H, Velazquez H. Metabolism of a potential 8-aminoquinoline antileishmanial drug in rat liver microsomes. Biochem Pharmacol 1985; 34: 181-8.
5. Jha TK, Sundar S, Thakur CP et al. 2005. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. Am J Trop Med Hyg 2005; 73: 1005-11.
6. Garnier T, Brown MB, Lawrence MJ et al. In vitro and in vivo studies on a topical formulation of sitamaquine dihydrochloride for cutaneous leishmaniasis. J Pharm Pharmacol 2006; 58: 1043-54.
7. Duenas-Romero AM, Loiseau PM, Saint-Pierre-Chazalet M. Interaction of sitamaquine with membrane lipids of Leishmania donovani promastigotes. Biochim Biophys Acta 2007; 1768: 246-52.
8. Rakotomanga M, Blanc S, Gaudin K et al. Miltefosine affects lipid metabolism in Leishmania donovani promastigotes. Antimicrob Agents Chemother 2007; 51: 1425-30.
9. Wassef M, Fioretti T, Dwyer D. Lipid analyses of isolated surface membranes of Leishmania donovani promastigotes. Lipids 1985; 20: 108-15.
10. Saint-Pierre-Chazalet M, Ben Brahim M, Le Moyec L et al. Membrane sterol depletion impairs miltefosine action in wild-type and miltefosine-resistant Leishmania donovani promastigotes. J Antimicrob Chemother 2009; 64: 993-1001.
11. Berdycheva O, Desbat B, Vaultier M et al. Interaction of natural polyamines and dimethylsilylanalogues with a phospholipid monolayer: a study by Brewster angle microscopy and PM-IRRAS. Chem Phys Lipids 2003; 125: 1-11.
12. Pilon M, Jordi W, de Kruiff B et al. Interactions of mitochondrial precursor protein apocytochrome c with phosphatidylserine in model membranes. A monolayer study. Biochim Biophys Acta 1987; 902: 207-16.
13. Perez-Victoria FJ, Gamarro F, Ouellette M et al. Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J Biol Chem 2003; 278: 49965-71.
14. Kabouridis PS, Janzen J, Magee AL et al. Cholesterol depletion disrupts lipid rafts and modulates the activity of multiple signaling pathways in T lymphocytes. Eur J Immunol 2000; 30: 954-63.
15. Simons K, Ehehalt R. Cholesterol, lipid rafts and disease. J Clin Invest 2002; 110: 597-603.
16. Anderson RG, Jacobson K. A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains. Science 2002; 296: 1821-5.
17. Rouquette-Jazdanian AK, Pelassy C, Breittmayer JP et al. Revaluation of the role of cholesterol in stabilizing rafts implicated in T cell receptor signaling. Cell Signal 2006; 18: 105-22.
18. Suzuki E, Tanaka AK, Toledo MS et al. Trypanosomatid and fungal glycolipids as infectivity factors and potential targets for development of new therapeutic strategies. Biochim Biophys Acta 2008; 1780: 362-9.
19. 2+ transport by digitonin-permeabilized Leishmania donovani. Effects of Ca2+, pentamidine and WR-6026 on mitochondrial membrane potential in situ. Biochem J 1992; 284: 463-7.
20. Vercesi A, Rodrigues C, Castisti R et al. Presence of a Na(+)/H(+) exchanger in acidocalcisomes of Leishmania donovani and their alkalization by anti-leishmanial drugs. FEBS Lett 2000; 473: 203-6.
21. Lopez-Martin C, Perez-Victoria JM, Carvalho L et al. Sitamaquine sensitivity in Leishmania species is not mediated by drug accumulation in acidocalcisomes. Antimicrob Agents Chemother 2008; 52: 4030-6.
22. Castanys-Munoz E, Perez-Victoria JM, Gamarro F et al. Characterization of an ABCG-like transporter from the protozoan parasite Leishmania with a role in drug resistance and transbilayer lipid movement. Antimicrob Agents Chemother 2008; 52: 3573-9.